The abovementioned findings contribute to our understanding of the comparative efficacy and safety of anti-TNF and anti-IL-17 therapies in the treatment of HS and highlight the potential of the latter as a promising alternative. This evidence concerns the gene TNF and histiocytic sarcoma.